The impact of disease duration on improvements in ACR responses and remission following abatacept treatment in patients with an inadequate response 2 to anti-TNF therapy in the ATTAIN trial. 69th Annual Scientific Meeting of the American-College-of-Rheumatology/40th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals Genovese, M., Luggen, M., Kremer, J., Sany, J., Aranda, R., Becker, J. C., White, A., Schiff, M., Dougados, M. WILEY-BLACKWELL. 2005: S137–S137

View details for Web of Science ID 000232207800296